Indaptus Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed October 22, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
A Schedule 13D/A (amended beneficial ownership statement) was filed on 2026-10-22 by Yao Yun regarding Indaptus Therapeutics, Inc. (market value ~$5.8M). The filing document itself is not readable in the provided text—only header metadata, addresses, and filing metadata are visible. No specific shareholdings, percentages, transaction amounts, or material changes are disclosed in the extractable text.
Why this rating
Filing is procedurally routine (Schedule 13D/A amendment), but substantive details missing—cannot assess shareholding magnitude or intent without readable content. Routine disclosure, likely small relative to $5.8M company.
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.